Radionuclide Drug Conjugates (RDCs) hold the potential to transform cancer treatment by offering effective, precise treatment and diagnosis with minimal side effects. Regulators have already approved several RDCs around the world, and more are in the pipeline as researchers seek to further improve their efficacy, safety, and personalization. RDCs have evolved from other branches of…
50 of the best-funded biotechs of 2023
As the year draws to a close, it is clear that molecular science and diagnostics is the hottest funding area in the biotech industry. In an analysis of 50 of the best-funded biotechs of 2023 focused on human health, molecular and science and diagnostics startups collectively attracting roughly $945 million, dwarfing the figures in other…